LENZ NASDAQ
LENZ Therapeutics, Inc.
1W: -15.9%
1M: -34.4%
3M: -47.9%
YTD: -58.4%
1Y: -75.2%
$6.72
+0.07 (+1.05%)
Weekly Expected Move ±13.6%
$5
$6
$7
$8
$9
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$208.5M
52W Range6.61-50.4
Volume709,357
Avg Volume952,424
Beta1.67
Dividend$7.21
Analyst Ratings
Company Info
CEOEvert Schimmelpennink
Employees6
SectorHealthcare
IndustryBiotechnology
IPO Date2024-03-22
Websitelenz-tx.com
445 Marine View Avenue
Solana Beach, CA 92014
US
Solana Beach, CA 92014
US
(858) 925-7000
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Latest News
Lenz outlines sales force reaching 15,000 eye care professionals by quarter end as VIZZ adoption actions roll out
Lenz (LENZ) Q1 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
Quant snapshot: Beachbody, Deutsche Telekom among top-rated names as IceCure Medical, Fold Holdings lag
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| George Jeffrey P. | P-Purchase | 5,592 | $8.92 | 2026-03-27 |
| Schimmelpennink Ever | P-Purchase | 28,089 | $8.95 | 2026-03-27 |
| Chevallard Daniel R. | P-Purchase | 7,500 | $8.57 | 2026-03-27 |
| Olsson Shawn | A-Award | 84,200 | $16.00 | 2026-01-02 |
| Olsson Shawn | A-Award | 14,000 | — | 2026-01-02 |